US6358060B2 - Two-stage transmucosal medicine delivery system for symptom relief - Google Patents

Two-stage transmucosal medicine delivery system for symptom relief Download PDF

Info

Publication number
US6358060B2
US6358060B2 US09/146,696 US14669698A US6358060B2 US 6358060 B2 US6358060 B2 US 6358060B2 US 14669698 A US14669698 A US 14669698A US 6358060 B2 US6358060 B2 US 6358060B2
Authority
US
United States
Prior art keywords
nicotine
user
delivery system
stage
base material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/146,696
Other versions
US20020018800A1 (en
Inventor
John M. Pinney
Jack E. Henningfield
Saul Shiffman
Joseph Gitchell
Edward J. Cone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JSR NTI LLC
Original Assignee
JSR LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/146,696 priority Critical patent/US6358060B2/en
Application filed by JSR LLC filed Critical JSR LLC
Priority claimed from US09/389,339 external-priority patent/US6344222B1/en
Priority claimed from AT99946722T external-priority patent/AT388687T/en
Priority claimed from ARP990104461A external-priority patent/AR022374A1/en
Assigned to JSR LLC reassignment JSR LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONE, EDWARD J., GITCHELL, JOSEPH, HENNINGFIELD, JACK E., PINNEY, JOHN M., SHIFFMAN, SAUL
Publication of US20020018800A1 publication Critical patent/US20020018800A1/en
Publication of US6358060B2 publication Critical patent/US6358060B2/en
Application granted granted Critical
Priority claimed from US11/037,098 external-priority patent/US20050123489A1/en
Assigned to JSR NTI LLC reassignment JSR NTI LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JSR LLC
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/81Addiction
    • Y10S514/813Tobacco

Abstract

A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g., cocaine, opiates and the like) and tobacco products, especially tobacco products containing nicotine.

Description

BACKGROUND OF THE INVENTION

The present invention relates to a two-stage medicine delivery system and method for making the two-stage medicine delivery system, wherein an initial dose of medicine is capable of achieving a rapid pharmacological effect, whereas a second dose achieves a prolonged pharmacological effect. The invention also is directed to an improved methodology for symptom relief, such as relief from cravings attributable to withdrawal (e.g., nicotine withdrawal).

The term “medicine”, as used herein, is not limited to substances which relieve pain, disease and/or infection. To the contrary, the term “medicine” encompasses virtually any therapeutic substance which can be effectively applied using the system of the present invention to achieve some desired result. Similarly, the term “lozenge” as used herein is not limited to products that are hard and have a flat, diamond-like shape, but rather encompasses any candy-like source of a therapeutic substance irrespective of its shape, such as gum. The term “lozenge” includes those substitutes by which medicine may be transmucosally delivered to the user.

Most conventional medicine delivery systems have limitations which make them less than ideal. One limitation relates to the speed of delivery. Few medicine delivery systems can provide a pharmacological effect within five minutes of use, much less within one to three minutes of use, and then provide sustainable (or on-demand) delivery for over 30 minutes. The delay in pharmacological effect is especially problematic in situations where the patient takes the medication in response to a stimulus. Examples of such situations include patients who take the medication in response to heart palpitations, diabetics who take the medication in response to noticeable glucose variations, addicts who take craving-reduction medicine in response to cravings, patients who take medication in response to panic attacks, and those seeking to stop smoking and experiencing a craving for a cigarette. In those patients, dangerous complications could arise if the medication is delivered ineffectually or at too fast of a rate.

Another limitation relates to variations in concentration of medicine achieved in the user's bloodstream. Few, if any, medicine delivery systems can provide substantially constant concentrations of medicine in the bloodstream. It is desirable, however, to provide a substantially constant concentration which remains at or near the level of pharmacological effect (LPE). Concentrations below the LPE may have little, if any, effect on the symptoms which the patient wishes to alleviate. Thus, when a medicine delivery system provides such low concentration, it is doing little, if anything, to alleviate the patient. Similarly, concentrations of medicine above the LPE typically are unnecessary, and can produce side-effects or reactions to the medication. There is consequently a need for a medicine delivery system which provides an initial dose of medicine sufficient to rapidly achieve a medicine concentration in the user's bloodstream at or near the LPE and which thereafter provides another more prolonged dose capable of maintaining the concentration of medicine in the user's bloodstream substantially constant at or near the LPE.

Conventional oral delivery systems fail to provide the foregoing combination of doses and the desirable results associated therewith. Typically, the conventional oral delivery system has a delay of 1-3 hours before reaching the LPE. Thereafter, it is unable to maintain a substantially constant concentration at or near the LPE. Instead, the desired pharmacological effect is achieved over a period of time by exceeding the concentration associated with the LPE, followed by a rapid decline in concentration below the LPE.

A typical curve CC representing the concentrations achieved by such an oral delivery system is illustrated in FIG. 1. The illustrated strategy disadvantageously exposes the patient to an over-dosage, as indicated by the portion of the concentration curve CC which appears far above the LPE line. The resulting overdosage tends to produce toxic side-effects or reactions to the medication.

In addition, the concentration curve CC remains below the LPE line for a significant period of time after the medication is taken. The length of this delay may vary and is affected by the speed of ingestion. This represents a potentially unacceptable delay in the desired pharmacological effect. This delay is particularly unacceptable where the medicine is used to reduce cravings. In those situations, the delay may be long enough that the patient succumbs to the craving. Smokers, for example, might smoke before the orally taken medicine can produce a reduction in the nicotine craving.

The concentration curve CC also drops below the LPE line after the over-dosage. This likewise represents a period of time between dosages where the patient is not receiving the benefit of the desired pharmacological effect.

Although the period of time between pills can be decreased in an attempt to reduce the magnitude of the overdosages, this becomes inconvenient to the patient and greatly increases the likelihood that the patient will not comply with the dosage requirements and therefore will not receive the full benefit of the desired pharmacological effect. In order to avoid non-compliance, the medicine delivery system should minimize the amount of activity required of the patient.

An additional problem with conventional oral medicine delivery systems which require stomach absorption of the medicine is the highly volatile enzymatic environment of the gastro-intestinal system. This environment can alter the medicine and reduce or eliminate its effectiveness.

In order to provide more immediate pharmacological effects, hypodermic injection has been used as a medicine delivery system. Such injection techniques, however, fail to provide constant concentrations of the medicine in the blood over prolonged periods of time.

FIG. 2 illustrates a typical concentration curve CC′ which represents the concentration of medicine in the blood over time when a conventional hypodermic injection technique is used. The concentration curve CC′ demonstrates how the initial dosage actually exceeds the LPE necessary to achieve the desired pharmacological effect. The hypodermic injection technique therefore exposes the patient to an over-dosage. This over-dosage, in turn, increases the likelihood of side-effects and adverse reactions. Another disadvantage associated with the conventional hypodermic injection technique is that it fails to provide a prolonged period of time during which the concentration remains at or near the LPE. Instead, the concentration curve CC′ reaches a peak soon after injection and progressively diminishes over time.

Yet another disadvantage associated with conventional hypodermic injection techniques is the pain associated with such injection techniques. Some patients are extremely disturbed by the notion of hypodermic injection. This limits the number of patients which will use the injection technique. Even the patients which do elect to use the hypodermic injection technique may be less likely to comply on a regular basis with dosage requirements when faced with the unpleasantness of frequent injections. In many cases, the injection technique requires medical personnel, privacy, and/or a stationary place to perform the injection. When all three requirements are present, the injection technique is extremely inconvenient to the patient.

Another conventional technique for delivering medicine involves an intravenous drip. The intravenous drip is capable of providing a rapid pharmacological effect and can be programmed to dispense medicine at a rate which achieves a substantially constant concentration of medicine in the blood, at or near the LPE. A typical curve CC″ representing the concentrations achieved by the intravenous drip technique is illustrated in FIG. 3.

The intravenous drip, however, requires trained medical personnel to supervise the delivery of medicine. This can result in delay because medical personal usually cannot respond immediately. The requirement of medical personnel also makes the intravenous drip technique very inconvenient for the patient. Another disadvantage associated with the intravenous drip technique is the need to insert a catheter subcutaneously. The initial insertion may be painful and uncomfortable, making this technique difficult on patients. In addition, the patient's mobility may be significantly hampered during the intravenous delivery of the medicine.

The intravenous drip technique is especially difficult to implement on an effective basis when the medicine is a craving reduction medicine. In those situations, it is impractical to have the patient meet with medical personnel to have a catheter inserted every time the patient experiences a craving.

Inhalation techniques also have been used to deliver medicine. Although such techniques may provide rapid and effective pharmacological effects, it is difficult to regulate the concentration of medicine in the blood over a prolonged period of time when such techniques are used.

Another conventional technique for delivering medicine involves the use of chewing gum. The chewing gum includes a medicine which is released into the mouth when the gum is chewed. Such gums can provide a relatively constant concentration of medicine, with slight variations from that consentration, in the chewer's blood. Accordingly, the LPE can be achieved using concentrations which do not deviate much higher than the LPE and do not vary significantly from the LPE. The chewing gum-based technique therefore advantageously avoids the over-dosage problems associated with conventional, orally administered medications which are not chewed but are immediately swallowed. A typical curve CC′″ representing the concentrations achieved by the chewing gum-based delivery systems is illustrated in FIG. 4.

A disadvantage associated with conventional gum chewing techniques, however, is the delay between the time when chewing begins and onset of the desired pharmacological effect. The delay typically is caused by the time it takes for sufficient medicine to be released from the gum and for that medicine to be absorbed into the bloodstream.

In the case of gums which are used to counteract cravings for nicotine-containing products, a substantial portion of the nicotine from such gums may be swallowed because of poor absorption in the mouth. Since nicotine, when swallowed, can cause adverse gastrointestinal symptoms, such as hiccupping and nausea, the conventional chewing gum technique can produce undesirable side-effects.

If the gum fails to provide a desired level of craving relief, attempts to obtain additional nicotine from the gum may cause increased feelings of nausea because of the frequent failure of users to absorb (rather than swallow) the nicotine. Thus, the effectiveness of conventional nicotine delivery gums may be difficult to adjust upwardly without experiencing an increased potential for nausea.

Despite the disadvantages associated with conventional nicotine delivering gum, there are commercially available versions of the gum, one of which is marketed using the trademark Nicorette™. Although the sensory effects of Nicorette™ provide an initial level of craving relief which is comparable to that which is produced by confectionery chewing gum, it is the delivery of nicotine to the bloodstream which produces objectively documented effects of craving relief. The delivery of nicotine to the bloodstream generally provides discriminable effects to the user (e.g., “feel the drug”), reduced desire for smoking, restoration of cognitive performance, and reversal of withdrawal-associated EEG disruption. See e.g., Henningfield et al., Pathophysiology of Tobacco Dependence, (1995), which appears in Bloom & Kupfer, Psychopharmacology: The Fourth Generation of Progress, Raven Press, pp. 1715-1729; Benowitz, Pharmacology of Nicotine: Addition and Therapeutics, Annual Review of Pharmacology and Toxicology, 36: 597-613.

Studies on the effects of Nicorette™ provide a basis for determining the doses at which various effects occur. For example, the approximately one milligram of nicotine delivered over 15-30 minutes by the 2 milligram version of Nicorette™ provides detectable effects, with minimal risk of nausea and undesirable pharmacologic consequences for most users. When the dose is increased, for example by using the 4 milligram version of Nicorette™ (which delivers about 2 milligrams of nicotine) or by administering multiple units of Nicorette™ (up to 4 units of the 4 milligram version of Nicorette™), the reliability of the craving reduction increases, but the probability of undesirable consequences, such as dizziness and nausea, also increases.

An important finding from the foregoing studies is that the craving-reducing effects of nicotine on the body are almost exclusively due to the nicotine which is absorbed into the bloodstream. Nicotine which remains in the saliva and/or is swallowed has very little effect beyond its flavor-induced sensory effects and stomach upset produced by excessive amounts of swallowed nicotine.

Nicotine from Nicorette™ reaches the bloodstream in several different ways. See e.g., Benowitz & Savanapridi, Determinants of Nicotine Intake While Chewing Nicotine Polacrilex Gum, Clinical Pharmacology and Therapeutics, 41(4), pp. 467-473. About 50% of the nicotine from the 2 and 4 milligram versions of the Nicorette™ is released from the gum during chewing. The rest of the nicotine typically remains in the gum and is discarded by the user.

Of the nicotine delivered by the 2 milligram version of the Nicorette™ gum to the saliva, about 0.8 milligram is absorbed through the membranes of the mouth (the buccal mucosa) and appears in the bloodstream. The remaining approximately 0.2 milligram is swallowed, of which 0.06 milligram survives first pass hepatic metabolism and appears in the bloodstream. The 4 milligram version of Nicorette™ gum achieves nicotine absorption values which are approximately twice those of the 2 milligram version.

Although the amount of nicotine absorption from Nicorette™ is related to the chewing rate and the time the saliva is held in the mouth, these variables are significant only at the extremes of rapid chewing versus little oral action, and frequent swallowing versus infrequent swallowing. Outside of such extremes, these variables have very little impact on nicotine absorption. Thus, it takes approximately 10 to 30 minutes to achieve absorption of the nicotine from Nicorette™ into the bloodstream, regardless of whether the “park and chew” (or “chew and park”) method is used or chewing at regular intervals (e.g., one chew per 4 seconds).

This initial delay, however, may be excessively long for someone who is trying to quit smoking. It is not unusual for a cigarette smoker to succumb to a nicotine craving within ten minutes of onset, especially if work or a stressful situation delays the use of the Nicorette™ beyond initial onset of the craving.

There is consequently a need for a nicotine delivery system which avoids the disadvantages associated with Nicorette™ gum (e.g., the initial delay in nicotine delivery) by providing rapid craving relief and which therefore minimizes the likelihood that a former smoker will succumb to his craving.

In providing such a nicotine delivery system, the documented effects of conventional nicotine sources, such as Nicorette™ gum, cigarettes, cigars, transdermal patches, and snuff have been considered to arrive at a delivery system which provides beneficial absorption characteristics.

Scientific data on the determinants of nicotine absorption through the membranes of the mouth, nose and epidermis, has been studied in detail since at least the 1940s. Much of this work has been reviewed in detail by the U.S. Food and Drug Administration (FDA). S. L. Tomar & J. E. Henningfield, for example, prepared a report entitled Review of the Evidence that pH is a Determinant of Nicotine Dosage from Oral use of Smokeless Tobacco, Tobacco Control, 6:219-225 (1997).

Based on the various studies, including studies of the epidermis and the buccal mucosa, the two major determinants of nicotine absorption are (1) the concentration of nicotine solution on the membrane and (2) the pH of the nicotine solution. The importance of these two determinants transcends a broad range of nicotine-containing applications, including transdermal patches, the nicotine-containing aerosol from tobacco smoke or the vapor inhaler marketed by Pharmacia, the micro environment of nicotine and moisture between the user's gum and cheek when moist snuff products are used, as well as the saliva-nicotine solution produced when Nicorette™ gum is chewed.

In the case of transdermal patches, for example, the initial form of dose control is provided by regulating the amount of nicotine which is applied against the epidermis. Once a predetermined amount of nicotine reaches the dermal membrane, the pH of the nicotine-containing solution determines the speed of absorption.

The Nicoderm™ patch, for example, carries 1-4 milligrams of nicotine in its surface layer to provide an initial burst of nicotine. The initial burst of nicotine is then followed by a controlled release from the patch reservoir. While the initial burst of nicotine is relatively rapid when compared to that provided by most other commercially available transdermal nicotine patches, it is still slow (about 30 minutes to achieve a significant increase in nicotine blood level) when compared to what can be achieved by delivery through the mouth. Dose-ranging studies were performed to determine the optimal amount of nicotine and amount and type of buffer to maximize absorption and to minimize skin irritation.

The relationship of the pH to the absorption rate of nicotine also was documented by O. Ferno in 1977, who concluded that unbuffered formulations were ineffective at nicotine delivery or relieving withdrawal symptoms. See Ferno, Development of a Chewing Gum Containing Nicotine and Some Comments on the Role Played by Nicotine in the Smoking Habit, in Steinfeld et al., Smoking & Health, Proceeding of the 3rd World Conference on Smoking and Health, Washington, D.C. (1977).

This led to the addition of 30 milligrams of sodium-based buffers to the gum formulations. The 2 milligram version of Nicorette™, for example, contains 10 milligrams of sodium bicarbonate and 20 milligrams of sodium carbonate. The 4 milligram version of Nicorette™ contains 30 milligrams of sodium carbonate.

The combination of buffers in Nicorette™ raises oral salivary pH from its typical value of about 6.9-7.3 to about 8.0 in 5-10 minutes. The act of chewing itself contributes to the rise in pH because chewing-stimulated saliva from the parotid gland contains some bicarbonate. By comparison, chewing an anti-acid tablet marketed under the trademark Tums™ (which contains calcium carbonate), produces an almost immediate increase in oral salivary pH to about 8.1.

Since Nicorette™ is physio-chemically structured so that its nicotine is evenly distributed throughout the gum, the release of nicotine depends on exposing fresh surface areas of the gum to the salivary substrate so that nicotine and buffer can be released into the saliva. The portion of nicotine which is unionized is free to be immediately absorbed through the buccal mucosa. Because the dissociation constant (pKa) of nicotine is 8.0, fifty percent of the nicotine is unionized and immediately free to be absorbed when the solution is at a pH of 8.0. At this pH, residual nicotine becomes unionized as the free nicotine is absorbed. There is consequently a steady but very rapid infusion of nicotine across the membrane after the appropriate pH is reached.

There have been several practical applications of the foregoing principles which provide guidance regarding the dosing range and speed for nicotine delivery systems. At least one of the “active” Nicorette™ placebo formulations used in the 1980s and early 1990s, for example, contained 0.5 milligram of nicotine without any buffer and was a useful placebo because it produced the oral sensory effects of nicotine with minimal absorption. Unlike chewing tobacco, which is actively chewed, moist snuff is used according to instructions from the major marketers of these products in a manner that is functionally similar to the chew and park method for Nicorette™. The physical effort required to manipulate the moist snuff, however, is less than that required by Nicorette™. The instructions direct the user to place the dose between the gum and cheek, and occasionally move or otherwise orally manipulate it. When such products are used, large differences in nicotine absorption have been observed as a function of two variables, namely, nicotine concentration and pH.

The relationship between pH and absorption rate is further illustrated by the differences between cigar smoke and cigarette smoke. Cigar smoke can provide rapid delivery of nicotine when held in the mouth because cigar smoke typically has a pH in the range of 7.5 to 8.0. Cigarette smoke, by contrast, typically has a pH between 5.5 and 6.0 and therefore must be inhaled to produce effective absorption. It is believed that effective nicotine absorption does not require pH levels greater than approximately 8.5 to 9.5. Further increases above 9.5 would be expected to produce a soapy and/or burning sensation in the mouth.

A need therefore exists for a nicotine delivery system which rapidly elevates a pH level in the user's mouth so that rapid absorption of nicotine into the bloodstream can be achieved, and which also delivers nicotine over a prolonged period of time to maintain a pharmacologically appropriate concentration of nicotine in the bloodstream.

SUMMARY OF THE INVENTION

A primary object of the present invention is to overcome the foregoing disadvantages associated with conventional medicine delivery systems, by providing a convenient, reliable, practical, and relatively painless medicine delivery system.

Another object of the present invention is to provide a two-stage medicine delivery system capable of providing initial and second doses of a craving reduction medicine, the combination of which rapidly reduces such cravings and provides protection from such cravings over a prolonged period of time beyond the initial dose.

Yet another object of the present invention is to provide a two-stage nicotine delivering gum capable of providing an initial dose of nicotine which is absorbed into the bloodstream within 5 minutes after chewing begins to achieve a pharmacologically effective concentration in the bloodstream, and also capable of providing a second dose of nicotine which keeps the concentration of nicotine in the bloodstream at or near the pharmacologically effective concentration for at least 20 minutes after chewing begins.

Still another object of the present invention is to provide a two-stage medicine delivering system which is convenient to use and which does not require trained medical personnel to administer the doses or require extensive user experience to provide a rapid pharmacological effect and/or mitigation of undesirable symptoms.

Another object of the present invention is to provide a medicine delivery system which provides a desired concentration of the medicine in the bloodstream within 5 minutes and preferably within 1-2 minutes of administration.

Yet another object of the present invention is to provide a medicine delivery system which keeps the concentration of the medicine in the bloodstream at or near the level of pharmacological effect (LPE), without significant overdosages.

To achieve these and other objects, the present invention provides a two-stage medicine delivery system. The two-stage medicine delivery system comprises means for providing an initial dose of medicine and means for providing a second dose of medicine. The initial dose of medicine is capable of achieving a rapid pharmacological effect. The second dose, by contrast, is capable of achieving a prolonged pharmacological effect.

The two-stage medicine delivery system preferably delivers a craving counteracting substance, and the rapid and prolonged pharmacological effects include a rapid and prolonged reduction of a craving.

Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form.

The two-stage medicine delivery system preferably includes means for releasing a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth.

The present invention also provides a method of making a medicine delivery system which reduces a craving when orally retained. According to the method, a base material is provided. The base material is adapted to be retained in a user's mouth. A loading compound is mixed into the base material so that the loading compound remains releasable and rapidly transmucosally absorbable to counteract a craving within 5 minutes after the base material is orally retained. In addition, a maintenance compound is mixed into the base material so that the maintenance compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract the craving for at least 20 minutes after oral retention of the base material begins.

Preferably, a buffer is also mixed into the base material so that the buffer remains releasable to elevate a pH level and facilitate transmucosal absorption of the loading and maintenance compounds within the user's mouth when the base material is orally retained. The buffer preferably is a bicarbonate type of buffer adapted to elevate the pH level to 7.5 to 9.5, preferably about 9.0, within 5 minutes after the base material is orally retained. Preferably, the base material is a gum base or a lozenge.

The present invention also provides a two-stage nicotine delivering product for use in counteracting cravings for nicotine-containing tobacco products. The product comprises a base, a nicotine loading compound, and a nicotine maintenance compound. The nicotine loading compound is mixed with the base so that oral actuation of the base causes the nicotine loading compound to be released into a user's mouth for transmucosal absorption within the first 5 minutes after oral actuation begins. The nicotine maintenance compound, by contrast, is mixed with the base so that oral actuation of the base causes the nicotine maintenance compound to be released into the user's mouth for prolonged transmucosal absorption which lasts at least 20 minutes beyond the first five minutes.

As indicated above, the present invention is well-suited for applications where the medicine is delivered orally, and more specifically, where the oral delivery of the medicine is performed via buccal transmucosal absorption. The present invention is quite useful as a craving reducer and can be adapted to reduce cravings for alcohol, food, drugs (e.g., cocaine, opiates and the like) and tobacco products, especially tobacco products containing nicotine.

As a nicotine delivery system, the present invention provides an initial dose of nicotine and a second dose of nicotine, the combination of which effectively counteracts a user's craving for cigarettes and other tobacco products. The present invention therefore can be used effectively to help smokers quit or reduce smoking.

The above and other objects and advantages will become more readily apparent when reference is made to the following description taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph illustrating medicine concentrations in the bloodstream when a conventional oral delivery system is used.

FIG. 2 is a graph illustrating medicine concentrations in the bloodstream when a conventional hypodermic injection technique is used.

FIG. 3 is a graph illustrating medicine concentrations in the bloodstream when a conventional intravenous drip technique is used.

FIG. 4 is a graph illustrating medicine concentrations in the bloodstream when a conventional gum-based nicotine delivery system is used.

FIG. 5 is a graph illustrating concentrations of medicine which are achieved in the bloodstream when a preferred medicine delivery system according to the present invention is used.

DETAILED DESCRIPTION OF THE INVENTION

In order to avoid delays in medicine delivery and overdosages, the present invention provides a two-stage medicine delivery system. The two-stage medicine delivery system comprises means for providing an initial dose of medicine and means for providing a second dose of medicine. The initial and second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively.

Preferably, the two-stage medicine delivery system delivers a craving counteracting substance, and the rapid and prolonged pharmacological effects provided by the system include a rapid and prolonged reduction in craving, respectively.

A preferred embodiment of the medicine delivery system is nicotine gum which delivers nicotine when chewed and which can be used to counteract cravings for nicotine-containing tobacco products. Although the nicotine gum form of the invention is preferred, it is understood that similar delivery systems may be provided in lozenge or other forms. Moreover, while the invention is preferably practiced in a manner relieving smoking withdrawal cravings, it has utility with other cravings, such as those related to eating disorders, stress, and the like, through suitable substitutions with the appropriate medicines.

The nicotine gum according to the preferred embodiment delivers the nicotine in a transmucosally absorbable form. The gum comprises a gum base, a nicotine loading compound, and a nicotine maintenance compound. The gum base can be implemented using one or a combination of several commercially available gum bases, some of which are commercially available from Fuisz Technologies. Preferably, the nicotine loading compound and/or the nicotine maintenance compound are substantially evenly distributed throughout the gum base so that distortion of the gum base's shape during chewing or oral manipulation does not significantly affect the amount and/or rate of nicotine release. In this regard, the gum base preferably does not include layers of different nicotine concentrations arranged to release different amounts of nicotine based on which layer of the gum is exposed.

The nicotine loading compound is mixed with the gum base so that chewing of the gum base causes the nicotine loading compound to be released into a chewer's mouth for transmucosal absorption within the first 5 minutes, and preferably within less than 3 minutes, after chewing begins. Preferably, the initial dose provided by the nicotine loading compound is between 0.2 and 0.7 milligram of nicotine. This initial dose is absorbed into the bloodstream within 5 minutes, and preferably within less than 3 minutes, after having been placed in the user's mouth. As a result, a loaded nicotine concentration in the bloodstream of 2 to 7 nanograms of nicotine per milliliter of blood (which is sufficient to provide craving relief) is achieved within about 5 minutes. Such a short delay in craving relief is acceptable to most former smokers and will not cause them to succumb to their cravings.

The nicotine maintenance compound, by contrast, is mixed with the gum base so that occasional chewing of the gum base causes the nicotine maintenance compound to be released into the chewer's mouth for prolonged transmucosal absorption which lasts at least 20 minutes beyond the first five minutes of use. The second dose provided by the nicotine maintenance compound is adapted to achieve a prolonged concentration of nicotine in the user's blood which is at least as high as a loaded nicotine concentration achieved in the user's blood by the initial dose.

Preferably, the nicotine maintenance compound is selected so that the prolonged concentration of nicotine is at least 10 nanograms per milliliter of blood and so that this prolonged nicotine concentration is maintained for at least 20 minutes and preferably 35 minutes after use begins.

The preferred nicotine delivering gum of the present invention achieves concentrations of nicotine in the bloodstream which, over time, substantially obey the concentration curve CCp illustrated in FIG. 5. Notably, the concentration curve CCp rises within 5 minutes after chewing begins and continues to rise to a level at or near the level of pharmacologic effect (LPE). Thereafter, the concentration curve CCp remains at or near the level of pharmacologic effect for at least 20 minutes, and preferably 35 minutes. The concentration curve CCp of the present invention advantageously does not exceed the LPE to such an extent that the user is exposed to an overdosage of nicotine.

In order to facilitate rapid craving relief, the nicotine gum of the preferred embodiment includes a releasable buffering agent which increases the pH level in the user's mouth prior to or along with release of the nicotine so that when nicotine is released into the saliva, it will be rapidly absorbed. The increased pH level thus enables rapid transmucosal absorption of the nicotine loading compound, as well as transmucosal absorption of the nicotine maintenance compound. Preferably, the buffering agent is adapted to elevate the pH level in the user's mouth to between about 7.5 and 9.5, preferably about 9.0, within 5 minutes of having been placed in the user's mouth.

Preferably, the nicotine loading compound is 0.2 to 0.7 milligram of nicotine salt, such as nicotine tartrate, which is mixed into the gum base. A preferred nicotine loading compound is 0.7 milligram of nicotine hydrogen tartrate.

The nicotine maintenance compound preferably consists of 1 to 4 milligrams of nicotine that may be held in an ion exchange resin gum, such as nicotine polacrilex. Alternatively, the nicotine maintenance compound can be provided using 1 to 4 milligrams of encapsulated nicotine salt. An exemplary nicotine maintenance compound is 1.5 milligrams of nicotine polacrilex, which in conjunction with the aforementioned preferred nicotine loading compound, achieves a total nicotine content of 2.2 milligrams of nicotine.

Preferably, the amount of buffering agent is 30 to 70 milligrams. A bicarbonate buffer may be used as the buffering agent. The type and amount of bicarbonate buffer preferably is selected to raise the pH level in the user's mouth to between about 7.5 and 9.5, preferably about 9.0, within 1 to 5 minutes after chewing begins and to maintain that pH level for about 15-30 minutes (i.e., the approximate range of time during which the gum will remain in the mouth). Preferably, the bicarbonate buffer is a sodium-free bicarbonate buffer. Alternatively, the buffer may be a carbonate buffer, which preferably is sodium-free. Calcium carbonate, for example, would be an appropriate sodium-free carbonate. Other examples of buffers which can be used include potasium citrate and dipotasium phosphate.

A buffer combination for the first dosage of sodium bicarbonate and sodium carbonate advantageously provides favorable mouth-feel and taste, and in this regard, may be preferred over other buffers. This buffer combination preferably is achieved using 20 milligrams of sodium bicarbonate and 10 milligrams of encapsulated sodium carbonate.

When the foregoing ingredients are combined, the resulting gum achieves a loaded nicotine concentration in the bloodstream of 2 to 7 nanograms per milliliter of blood within 5 minutes after use begins (stage 1) and eventually achieves a maintenance concentration of nicotine in the bloodstream of at least 5 nanograms of nicotine per milliliter of blood for an additional 20 to 35 minutes (stage 2). Notably, the gum sustains release of the nicotine in addition to providing a rapid initial release and absorption of the nicotine. This represents a significant advance over conventional gums, which generally provide a sustainable release without providing rapid release and absorption.

The rapid absorption of nicotine provided by the present invention provides additional advantages. Some research indicates that, even if the same total amount of nicotine is delivered, the psychoactive effects of nicotine on craving relief are enhanced when the rate of absorption increases. Thus, the present invention's ability to provide a prompt and rapid rise in the concentration of nicotine in the blood makes the present invention a significantly more effective craving reducer.

Advantageously, the present invention provides the rapid rise in absorption without replicating the explosive bolus associated with nasal nicotine sprays. Such sprays typically deliver 1 milligram of nicotine to the bloodstream, but pose a more significant risk of abuse and addiction. The present invention more effectively avoids such risks by employing transmucosal absorption, as opposed to the more rapid nasal absorption.

The present invention also provides the desired first and second doses regardless of whether the gum is chewed at regular intervals or is manipulated using the “park and chew” (or “chew and park”) method.

The present invention also provides a method of making a medicine delivery system, and more specifically, a medicine delivery system which reduces a craving when orally retained. According to the method, a base material is provided. The base material is adapted to be retained in a user's mouth. A loading compound is mixed into the base material so that the loading compound remains releasable and rapidly transmucosally absorbable to counteract a craving within 5 minutes after the base material is orally retained. In addition, a maintenance compound is mixed into the base material so that the maintenance compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract the craving for at least 20 minutes after the base material is placed in the mouth.

A buffer preferably is mixed into the base material so that the buffer remains releasable to elevate a pH level and facilitate transmucosal absorption of the loading and maintenance compounds within the user's mouth when the base material is orally retained. The buffer preferably is a bicarbonate buffer adapted to elevate the pH level to about 7.5 to 9.5 (preferably, about 9.0) within 5 minutes after the base material is orally retained. Preferably, the base material is a gum base, and the loading and maintenance compounds are therapeutic substances which counteract a user's cravings.

According to a preferred application of the method, the therapeutic substance is nicotine and the exemplary nicotine loading and maintenance compounds described above are used as the loading and maintenance compounds of the method. In addition, the exemplary buffering agent described above can be used as the buffering agent described in connection with the method.

The present invention, as indicated above, is well-suited for applications where the medicine is delivered orally, and more specifically, where the oral delivery of the medicine is performed via transmucosal absorption. The present invention is quite useful as a craving reducer and can be adapted to reduce cravings for alcohol, food, drugs (e.g., cocaine, opiates, and the like), and tobacco products, especially tobacco products containing nicotine.

The present invention also may include flavorants which are added to the base and which provide flavor, such as mint flavor, upon oral actuation. Spearmint oil or other types of mint flavor, sorbitol, xylitol, and the like are examples of the types of flavorants which can be added to the present invention. Other flavorants will become readily apparent to those of ordinary skill in the art upon reading the instant disclosure.

As an oral nicotine delivery system, the present invention provides an initial dose of nicotine and a second dose of nicotine, the combination of which effectively counteracts a user's craving for cigarettes and other tobacco products. The present invention therefore can be used effectively to help former smokers avoid smoking.

While the preferred ranges of nicotine concentrations and amounts of nicotine have been described above, it is understood that the invention is not limited to such concentrations and amounts. To the contrary, the concentrations and amounts can be adjusted depending on the target population. Some target populations require more nicotine than others. For example, smokers in Mexico generally tend to require less nicotine than many other population groups to achieve the same amount of craving relief. Heavy smokers versus light smokers also will have different nicotine requirements in general. Other factors which may affect the nicotine concentrations and amounts for different target populations include environmental, geographic, and biological differences between the target populations. Thus, it is well within the scope and spirit of the present invention to adjust the concentrations and amounts of nicotine accordingly.

In addition, the medicine need not be released in separate loading and maintenance dosages but rather can be releasable from the gum in a single initial form or manner which remains in the mouth or is reabsorbed and re-released by the base material during oral manipulation. In such an arrangement, the maintenance dosage is provided to the bloodstream by appropriately releasing a maintenance dose of buffer over the prolonged period of time, thereby facilitating the desired rate of transmucosal absorption over the maintenance period.

While this invention has been described as having a preferred embodiment, it is understood that the invention is not limited to the illustrated and described features. To the contrary, the invention is capable of further modifications, usages, and/or adaptations following the general principals of the invention and therefore includes such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains, and as may be applied to the central features set forth above, and which fall within the scope of the appended claims.

Claims (74)

We claim:
1. A two-stage medicine delivery system, comprising:
a gum, means cooperating with said gum for providing an initial dose of a medicine capable of achieving a rapid transmucosally absorbable pharmacological effect upon oral manipulation of said gum and a second dose of said medicine capable of achieving a prolonged transmucosally absorbable pharmacological effect upon subsequent oral manipulation of said gum, said medicine being evenly distributed throughout said gum.
2. The two-stage medicine delivery system of claim 1, wherein said initial and second doses are separate forms of said medicine.
3. The two-stage medicine delivery system of claim 1, wherein the medicine is nicotine.
4. The two-stage medicine delivery system of claim 2, wherein said medicine is nicotine.
5. The two-stage medicine delivery system of claim 4, wherein one of said doses is a nicotine salt and the other of said doses is nicotine polacrilex.
6. The two-stage medicine delivery system of claim 3, wherein said initial dose releases between 0.2 and 0.7 milligrams of nicotine within 5 minutes of having been placed in a user's mouth.
7. The two-stage medicine delivery system of claim 6, wherein said means second dose maintains, for at least 20 minutes a prolonged concentration of nicotine in the user's blood which is at least as high as the nicotine concentration achieved in the user's blood by the initial dose.
8. The two-stage medicine delivery system of claim 7, wherein the initial nicotine concentration is at least 2 nanograms of nicotine per milliliter of blood.
9. The two-stage medicine delivery system of claim 8, wherein the prolonged concentration of nicotine is at least 10 nanograms of nicotine per milliliter of blood.
10. The two-stage medicine delivery system of claim 9, further comprising means for
a buffering agent is dispersed within said gum and increases a pH
level in the user's mouth to facilitate transmucosal absorption of nicotine.
11. The two-stage medicine delivery system of claim 1, further comprising
a buffering agent and means for releasing said buffering agent so that the pH level in a user's mouth is increased to facilitate absorption of said medicine when said two-stage medicine delivery system is placed in the user's mouth.
12. The two-stage medicine delivery system of claim 11, wherein said medicine is nicotine.
13. The two-stage medicine delivery system of claim 12, wherein:
said buffering agent is adapted to elevate the pH level in the user's mouth to between about 7.5 and 9.5 within 5 minutes of having been placed in the user's mouth;
said means for providing adapted to achieve an initial nicotine concentration in the user's blood of between 2 nanograms of nicotine per milliliter of blood and 7 nanograms of nicotine per milliliter of blood, within 5 minutes of having been placed in the user's mouth; and
said means for providing is adapted to increase the concentration of nicotine in the user's blood beyond the initial nicotine concentration to achieve a prolonged concentration of nicotine in the user's blood of at least 10 nanograms of nicotine per milliliter of blood, and is further adapted to maintain said prolonged concentration of nicotine for at least 20 minutes.
14. The two-stage medicine delivery system of claim 1, wherein said medicine is a craving counteracting substance, and said rapid and prolonged therapeutic effects include a rapid and prolonged reduction of a craving.
15. A two-stage nicotine delivering product for use in counteracting cravings for nicotine-containing tobacco products comprising:
a base;
a nicotine loading compound mixed with the base so that oral actuation of the base causes the nicotine loading compound to be released into a user's mouth for transmucosal absorption within the first 5 minutes after oral actuation begins; and
a nicotine maintenance compound mixed with the base so that oral actuation of the base causes the nicotine maintenance compound to be released into the user's mouth for prolonged transmucosal absorption which lasts at least 20 minutes beyond said first five minutes.
16. The two-stage nicotine delivering product of claim 15, wherein said nicotine loading compound is 0.2 to 0.7 milligrams of a nicotine salt.
17. The two-stage nicotine delivering product of claim 16, wherein said nicotine salt is nicotine tartrate.
18. The two-stage nicotine delivering product of claim 15, wherein said nicotine maintenance compound is 1 to 4 milligrams of nicotine in an ion exchange resin gum.
19. The two-stage nicotine delivering product of claim 18, wherein said nicotine in an ion exchange resin gum is nicotine polacrilex.
20. The two-stage nicotine delivering product of claim 15, wherein said nicotine maintenance compound is 1 to 4 milligrams of encapsulated nicotine salt.
21. The two-stage nicotine delivering product of claim 15, wherein said nicotine maintenance compound is adapted to maintain, for said at least 20 minutes, a prolonged concentration of nicotine in the user's blood which is at least as high as a loaded nicotine concentration achieved in the user's blood by said nicotine loading compound.
22. The two-stage nicotine delivering product of claim 21, wherein said loaded nicotine concentration is at least 2 nanograms of nicotine per milliliter of blood.
23. The two-stage nicotine delivering product of claim 22, wherein said prolonged concentration of nicotine is at least 10 nanograms of nicotine per milliliter of blood.
24. The two-stage nicotine delivering product of claim 23, further comprising a buffering agent mixed with the base, for raising a pH level in the user's mouth to facilitate transmucosal absorption of the nicotine loading compound and the nicotine maintenance compound.
25. The two-stage nicotine delivering product of claim 23, further comprising 30-70 milligrams of a buffering agent mixed with the base, for raising a pH level in the user's mouth to between about 7.5 and 9.5 within 5 minutes of when oral actuation begins, to facilitate transmucosal absorption of the nicotine loading compound and the nicotine maintenance compound.
26. The two-stage nicotine delivering product of claim 15, further comprising a buffering agent mixed with the base, for raising a pH level in the user's mouth to facilitate transmucosal absorption of the nicotine loading compound and the nicotine maintenance compound.
27. The two-stage nicotine delivering product of claim 26, wherein:
said buffering agent is adapted to elevate the pH level in the user's mouth to between about 7.5 and 9.5 within 5 minutes of when oral actuation begins;
said nicotine loading compound is adapted to achieve a nicotine loaded concentration in the user's blood between 2 nanograms of nicotine per milliliter of blood and 7 nanograms of nicotine per milliliter of blood, within 5 minutes of when oral actuation begins; and
said nicotine maintenance compound is adapted to increase the concentration of nicotine in the user's blood beyond the nicotine loaded concentration to achieve a prolonged concentration of nicotine in the user's blood of at least 10 nanograms of nicotine per milli-liter of blood, and is further adapted to maintain said prolonged concentration of nicotine for at least 20 minutes.
28. A method of making a medicine delivery system which reduces a craving when orally retained, said method comprising the steps of:
providing a base material which is adapted to be retained in a user's mouth;
mixing a loading compound into the base material so that said loading compound remains releasable and rapidly transmucosally absorbable to counteract said craving within 5 minutes after the base material is orally retained; and
mixing a maintenance compound into the base material so that said maintenance compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract said craving for at least 20 minutes after oral retention of the base material begins.
29. The method of claim 28, further comprising the step of:
mixing a buffer into the base material so that said buffer remains releasable to elevate a pH level and facilitate transmucosal absorption of said loading and maintenance compounds within the user's mouth when the base material is orally retained.
30. The method of claim 29, wherein said buffer is a bicarbonate buffer adapted to elevate said pH level to about 7.5 to 9.5 within 5 minutes after said base material is orally retained.
31. The method of claim 28, wherein said base material is a gum base.
32. The method of claim 28, wherein said craving is a nicotine craving and said loading compound is 0.2 to 0.7 milligrams of nicotine salt.
33. The method of claim 28, wherein said craving is a nicotine craving and said maintenance compound is 1 to 4 grams of nicotine in an ion exchange resin gum.
34. The method of claim 33, wherein said 1 to 4 grams of nicotine in an ion exchange resin gum is nicotine polacrilex.
35. The method of claim 28, wherein said craving is a nicotine craving and said maintenance compound is encapsulated nicotine salt.
36. The two-stage medicine delivery system of claim 1, further comprising:
a buffering agent dispersed throughout said gum.
37. The two-stage medicine delivery system of claim 36, wherein said buffering agent is present in sufficient amount to elevate the pH in a user's mouth to between about 7.5 and 9.5.
38. The two-stage medicine delivery system of claim 37, wherein the buffering agent is present in sufficient amount to elevate the pH in a user's mouth for at least 15 minutes.
39. The two-stage medicine delivery system of claim 36, wherein the buffering agent is selected from the group consisting of bicarbonate and carbonate buffers.
40. The two-stage medicine delivery system of claim 36, wherein said buffer is a sodium free buffer.
41. The two-stage medicine delivery system of claim 36, wherein said buffer is selected from the group consisting of calcium carbonate, potassium citrate, and dipotassium phosphate.
42. The two-stage medicine delivery system of claim 41, wherein there is about 30 to 70 milligrams of buffering agent dispersed throughout said gum.
43. A method of making a delivery system which reduces craving when orally manipulated, said method comprising the steps of:
providing a base material which is adapted to be retained in the mouth of a user and to be manipulated by the user; and
providing a craving reduction compound, the compound being rapidly transmucosally absorbable upon oral manipulation to counteract a craving within about 5 minutes after the base material is orally manipulated and the compound remains releasable and transmucosally absorbable over a prolonged period of time to counteract the craving for at least about 20 minutes after oral manipulation of the base material commences;
mixing the craving reduction compound with the base material; and
forming the mixture of the base material and oral reduction compound into a unit suitable for being retained in the mouth and thereafter orally manipulated.
44. The method of claim 43, including the step of providing as the base material a gum base.
45. The method of claim 44, including the step of forming the mixture into one of a gum and a lozenge.
46. The method of claim 44, including the step of forming the mixture into a gum.
47. The method of claim 43, including the step of providing as the craving reduction compound nicotine.
48. The method of claim 47, including the step of providing the nicotine in the form of at least one of a nicotine salt and nicotine polacrilex.
49. The method of claim 48, including the step of providing the nicotine in only one form.
50. The method of claim 43, including the step of providing a buffering agent, and mixing the buffering agent into the base material.
51. The method of claim 50, including the step of mixing sufficient buffering agent to elevate the pH of a user's mouth to between about 7.5 and 9.5.
52. The method of claim 51, including the step of providing sufficient buffering agent to elevate the pH for at least about 15 minutes.
53. The method of claim 50, including the step of providing the buffering agent from the group consisting of sodium free buffers.
54. The method of claim 50, including the step of providing the buffering agent from the group consisting of bicarbonate and carbonate buffers.
55. The method of claim 50, including the step of providing the buffering agent from the group consisting of calcium carbonate, potassium citrate, and dipotassium phosphate.
56. The method of claim 50, including the step of mixing from about 30 milligrams to about 70 milligrams of buffering agent per unit.
57. A two-stage active agent delivery system that reduces cravings, comprising:
an orally manipulatable gum base material;
a buffer dispersed within said base material; and
an active ingredient intermixed with said base material and said buffer, said active ingredient cooperating with said buffer upon oral manipulation of the base material for therewith causing release of an initial dose of an active agent achieving a rapid transmucosally absorbable pharmacological effect reducing a craving and releasing a second dose of the active agent achieving a prolonged transmucosally absorbable pharmacological effect reducing the craving.
58. The system of claim 57, wherein said buffer is present in sufficient amount to elevate the pH in a user's mouth to between about 7.5 and 9.5.
59. The system of claim 57, wherein said buffer is present in sufficient amount to elevate the pH in a user's mouth for at least 15 minutes.
60. The system of claim 57, wherein the buffer is selected from the group consisting of bicarbonate and carbonate buffers.
61. The system of claim 57, wherein said buffer is a sodium free buffer.
62. The system of claim 57, wherein said buffer is selected from the group consisting of calcium carbonate, potassium citrate, and dipotassium phosphate.
63. The system of claim 57, wherein there is about 30 to 70 milligrams of buffer dispersed throughout said base material.
64. The system of claim 57, wherein said active ingredient is nicotine.
65. The system of claim 64, wherein said nicotine is selected from the group consisting of nicotine salts and nicotine polacrilex.
66. The system of claim 65, wherein the nicotine is of a single form.
67. The system of claim 65, wherein the nicotine is of at least two forms.
68. The system of claim 65, wherein the initial dose release from about 0.2 to about 0.7 milligrams of nicotine within about 5 minutes.
69. The system of claim 68, wherein the initial dose achieves a concentration of about 2 nanograms of nicotine per milliliter of blood.
70. The system of claim 69, wherein the second dose achieves a concentration of about 10 nanograms of nicotine per milliliter of blood.
71. The system of claim 57, wherein the second dose achieves a concentration in the blood of the active ingredient exceeding the concentration achieved by the initial dose.
72. The system of claim 71, wherein the second dose concentration is maintained for at least about 20 minutes.
73. A two-stage nicotine delivery system that reduces tobacco cravings, comprising:
an orally manipulatable gum base material;
a non-sodium buffer dispersed within said gum base material; and
nicotine evenly distributed throughout said gum base material and intermixed with said buffer, said nicotine cooperating with said buffer upon oral manipulation of the gum base material by a user for therewith causing release of an initial dose of nicotine achieving a rapid transmucosally absorbable pharmacological effect reducing tobacco craving and thereafter releasing a second dose of the nicotine upon subsequent oral manipulation of the gum base material by the user for achieving a prolonged transmucosally absorbable pharmacological effect reducing the tobacco craving.
74. A two stage active ingredient delivery system, comprising:
a) a base suitable for being received within the oral cavity of a user;
b) a buffer uniformly distributed throughout said base for being released into the oral cavity of the user for thereby causing the pH within the oral cavity to be elevated; and
c) an active ingredient uniformly distributed throughout said base so that when the base is placed with the oral cavity at least some of the buffer is released and thereby elevates the pH within the oral cavity and an initial dose of said active ingredient is release sufficient to achieve a rapid transmucosally absorbable pharmacological effect and further release of said active ingredient is sufficient to achieve a prolonged transmucosally absorbable pharmacological effect.
US09/146,696 1998-09-03 1998-09-03 Two-stage transmucosal medicine delivery system for symptom relief Expired - Lifetime US6358060B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/146,696 US6358060B2 (en) 1998-09-03 1998-09-03 Two-stage transmucosal medicine delivery system for symptom relief

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US09/146,696 US6358060B2 (en) 1998-09-03 1998-09-03 Two-stage transmucosal medicine delivery system for symptom relief
US09/389,339 US6344222B1 (en) 1998-09-03 1999-09-02 Medicated chewing gum delivery system for nicotine
ARP990104461A AR022374A1 (en) 1998-09-03 1999-09-03 Medication delivery system of nicotine gum to
MYPI99003826A MY124346A (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
AT99946722T AT388687T (en) 1998-09-03 1999-09-03 Medicament administration of nicotin in the form of gum
AU59068/99A AU776019B2 (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
DK99946722T DK1107730T3 (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
MXPA01002300A MXPA01002300A (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine.
CA2346330A CA2346330C (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
PCT/US1999/020105 WO2000013662A2 (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
EP99946722A EP1107730B1 (en) 1998-09-03 1999-09-03 Medicated chewing gum delivery system for nicotine
DE69938347T DE69938347T2 (en) 1998-09-03 1999-09-03 Medicament administration of nicotin in the form of gum
US10/098,307 US6893654B2 (en) 1998-09-03 2002-03-18 Two-stage transmucosal medicine delivery system for symptom relief
AU2004231204A AU2004231204B2 (en) 1998-09-03 2004-11-19 Medicated chewing gum delivery system for nicotine
US11/037,098 US20050123489A1 (en) 1998-09-03 2005-01-19 Medicated chewing gum delivery system for nicotine
US11/129,323 US20050214229A1 (en) 1998-09-03 2005-05-16 Two-stage transmucosal medicine delivery system for symptom relief
US11/522,441 US20070014887A1 (en) 1998-09-03 2006-09-18 Medicated chewing gum delivery system for nicotine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/389,339 Continuation-In-Part US6344222B1 (en) 1998-09-03 1999-09-02 Medicated chewing gum delivery system for nicotine
US10/098,307 Continuation US6893654B2 (en) 1998-09-03 2002-03-18 Two-stage transmucosal medicine delivery system for symptom relief

Publications (2)

Publication Number Publication Date
US20020018800A1 US20020018800A1 (en) 2002-02-14
US6358060B2 true US6358060B2 (en) 2002-03-19

Family

ID=22518571

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/146,696 Expired - Lifetime US6358060B2 (en) 1998-09-03 1998-09-03 Two-stage transmucosal medicine delivery system for symptom relief
US10/098,307 Expired - Fee Related US6893654B2 (en) 1998-09-03 2002-03-18 Two-stage transmucosal medicine delivery system for symptom relief
US11/129,323 Abandoned US20050214229A1 (en) 1998-09-03 2005-05-16 Two-stage transmucosal medicine delivery system for symptom relief

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/098,307 Expired - Fee Related US6893654B2 (en) 1998-09-03 2002-03-18 Two-stage transmucosal medicine delivery system for symptom relief
US11/129,323 Abandoned US20050214229A1 (en) 1998-09-03 2005-05-16 Two-stage transmucosal medicine delivery system for symptom relief

Country Status (1)

Country Link
US (3) US6358060B2 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039596A1 (en) * 1997-11-14 2002-04-04 Hartoun Hartounian Production of multivesicular liposomes
US20020162563A1 (en) * 2001-05-01 2002-11-07 Williams Jonnie R. Smokeless tobacco product
WO2003039518A1 (en) * 2001-11-02 2003-05-15 Smithkline Beecham Corporation Oral controlled release forms useful for reducing or preventing nicotine cravings
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
US20040248946A1 (en) * 2001-12-10 2004-12-09 Knight Joseph R Beverage treated with nicotine
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
US6893654B2 (en) * 1998-09-03 2005-05-17 Jsr, Llc Two-stage transmucosal medicine delivery system for symptom relief
US20050123489A1 (en) * 1998-09-03 2005-06-09 Jsr, Llc Medicated chewing gum delivery system for nicotine
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20050287226A1 (en) * 2001-12-18 2005-12-29 Sisco Tamea R High potency clinical anti-craving treatment and method of use
US20060105023A1 (en) * 2001-12-10 2006-05-18 Knight Joseph R Treatment of neurological disorders with nicotine
US20060120974A1 (en) * 1999-05-13 2006-06-08 Fluid Technologies Limited Of Great Britain Nicotine delivery systems
US20060276501A1 (en) * 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070231361A1 (en) * 2006-03-28 2007-10-04 Medtronic Vascular, Inc. Use of Fatty Acids to Inhibit the Growth of Aneurysms
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20080020050A1 (en) * 2006-07-21 2008-01-24 Chau Tommy L Medicinal delivery system, and related methods
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20090130179A1 (en) * 2007-11-16 2009-05-21 Cadbury Adams Usa Llc Confectionery compositions including markings for delivery of actives
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100260690A1 (en) * 2007-09-18 2010-10-14 Arne Kristensen Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
US20110038915A1 (en) * 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
US20110064783A1 (en) * 2008-05-26 2011-03-17 Birgitte Bang-Madsen Flavor Impregnation Of A Chewing Gum Core
US20110129517A1 (en) * 2008-05-21 2011-06-02 Novartis Ag Tablettable chewing gums
US20110214681A1 (en) * 2008-09-17 2011-09-08 Niconovum Ab Process for preparing snuff composition
WO2011139684A2 (en) 2010-04-28 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
WO2011139811A1 (en) 2010-05-07 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
WO2013043866A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
WO2013059592A1 (en) 2011-10-21 2013-04-25 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
WO2017093941A1 (en) 2015-12-03 2017-06-08 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
WO2017098443A1 (en) 2015-12-10 2017-06-15 Niconovum Usa, Inc. Protein-enriched therapeutic composition of a nicotinic compound
US10463069B2 (en) 2013-12-05 2019-11-05 Juul Labs, Inc. Nicotine liquid formulations for aerosol devices and methods thereof
WO2019239356A1 (en) 2018-06-15 2019-12-19 R. J. Reynolds Tobacco Company Purification of nicotine

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab A device for administering a substance to the front of a subject's oral cavity
AR045076A1 (en) * 2003-07-24 2005-10-12 Smithkline Beecham Plc Film composition that is orally dissolved film dissolved multicomponent orally, using the film composition and the film that is orally dissolved to prepare a medicament, oral dosage form and method for preparing the film composition that
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
WO2006058536A1 (en) * 2004-11-30 2006-06-08 Fertin Pharma A/S Method of providing fast relief to a user of a nicotine chewing gum
US20080075674A1 (en) * 2006-09-25 2008-03-27 Dupratt Brian D Cough Suppressor
MX2009005671A (en) * 2006-12-01 2009-06-08 Cima Labs Inc Oral transmucosal nicotine dosage form.
US20090214442A1 (en) * 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
CA2704209C (en) * 2007-10-31 2017-02-28 Mcneil-Ppc, Inc. Orally disintegrative dosage form
BRPI0822655A2 (en) 2008-06-04 2015-06-30 Colgate Palmolive Co Oral Care Implement and System
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US8313768B2 (en) * 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110070301A1 (en) * 2009-09-24 2011-03-24 Luber Joseph R Orally transformable tablets
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
EP2768477A1 (en) * 2011-10-19 2014-08-27 Fertin Pharma A/S Nicotine chewing gum with improved utilization of nicotine
WO2013091631A1 (en) * 2011-12-22 2013-06-27 Fertin Pharma A/S Method of releasing nicotine from chewing gum
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
AR096223A1 (en) * 2013-05-10 2015-12-16 Glaxosmithkline Llc Nicotine lozenge for oral administration
WO2015068058A1 (en) 2013-11-06 2015-05-14 Rk Technology & Investments Pte. Ltd. Tobacco free 'niconuts'and the process thereof
KR20160107254A (en) 2014-01-10 2016-09-13 존슨 앤드 존슨 컨수머 인코포레이티드 Process for making tablet using radiofrequency and lossy coated particles
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1038227A (en) 1911-07-25 1912-09-10 Nathan Sulzberger Chewing-gum containing pharmaceutical preparations.
US2262087A (en) 1940-05-21 1941-11-11 White Lab Inc Chewing gum tablet
US2536168A (en) 1947-09-29 1951-01-02 Clark & Clark Co Amphetamine chewing gum
US3845217A (en) 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US3877468A (en) 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3984574A (en) 1975-04-11 1976-10-05 Wm. Wrigley Jr. Company Non-tack chewing gum composition
US4139589A (en) 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4163777A (en) 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4238475A (en) 1979-08-01 1980-12-09 Life Savers Inc. Chewing cum capable of releasing finely divided water-insoluble materials therefrom
US4276890A (en) 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US4311691A (en) 1979-10-09 1982-01-19 Fichera Anthony T Tobacco smoking inhibitor
US4515769A (en) 1981-12-01 1985-05-07 Borden, Inc. Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same
US4620982A (en) 1982-12-17 1986-11-04 Roquette Freres Pastilles of the lozenge type based on crystalline sorbitol or fructose and process for their manufacture
US4639368A (en) 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4711784A (en) 1986-01-07 1987-12-08 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products
US4806356A (en) 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US4832994A (en) 1987-09-02 1989-05-23 Fey Michael S Anti-smoking oral composition
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4907605A (en) 1985-05-24 1990-03-13 Advanced Tobacco Products, Inc. Oral tabacco substitute
US4963369A (en) 1989-01-19 1990-10-16 Wm. Wrigley Jr. Co. Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US4967773A (en) 1986-06-26 1990-11-06 Shaw Alec S W Nicotine containing lozenge
US4971079A (en) 1982-02-22 1990-11-20 Talapin Vitaly I Pharmaceutical preparation possessing antinicotine effect and method of producing same in a gum carrier
US4971806A (en) 1984-01-31 1990-11-20 Warner-Lambert Company Multi-layered chewing gum composition having different rates of flavor release
US4983378A (en) 1988-11-22 1991-01-08 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US4985252A (en) 1987-04-07 1991-01-15 R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition
US5069904A (en) 1989-01-06 1991-12-03 Elan Corporation, Plc Method of using nicotine in the treatment of conditions susceptible to said treatment
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5139787A (en) 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5147648A (en) 1986-01-16 1992-09-15 Christian Bannert Method of improving the adhesiveness of gels to mucosae
US5147654A (en) 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5154939A (en) 1989-04-19 1992-10-13 Wm. Wrigley Jr. Company Use of salt to improve extrusion encapsulation of chewing gum ingredients
US5154927A (en) 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5158772A (en) 1991-09-23 1992-10-27 Davis Walter B Unique bacterial polysaccharide polymer gel in cosmetics, pharmaceuticals and foods
GB2255892A (en) 1991-05-24 1992-11-25 Charwell Consumer Prod Smoking substitute preparation
US5198251A (en) 1989-04-19 1993-03-30 Wm. Wrigley Jr. Company Gradual release structures for chewing gum
US5244668A (en) 1988-10-14 1993-09-14 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
WO1993020821A1 (en) 1992-04-21 1993-10-28 Kabi Pharmacia Ab Agents for treating substance abuse disorders
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5302394A (en) 1992-07-14 1994-04-12 Mcneil-Ppc, Inc. Dextromethorphan continuous lozenge manufacturing process
US5312626A (en) 1991-07-01 1994-05-17 Gerhard Gergely Lozenge or chewable tablet
US5334390A (en) 1992-11-05 1994-08-02 Neil Solomon Method for tabacco dehabituation
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5364627A (en) 1989-10-10 1994-11-15 Wm. Wrigley Jr. Company Gradual release structures made from fiber spinning techniques
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US5399354A (en) 1993-05-28 1995-03-21 Mcneil-Ppc, Inc. Process for making a hard-candy based oral pharmaceutical lozenge containing an antacid
WO1995012399A1 (en) 1993-11-01 1995-05-11 Pharmacia Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
CA2109895A1 (en) 1993-11-24 1995-05-25 Richard Neil Irwin Nicotine containing oral preparation
US5437872A (en) 1989-08-25 1995-08-01 Bioglan Laboratories Ltd. Pharmaceutical compositions and a device for administering the same
US5462754A (en) 1992-03-03 1995-10-31 Wm. Wrigley Jr. Company Abhesive chewing gum with improved sweetness profile
US5487902A (en) 1989-07-24 1996-01-30 Fertin Laboratories Ltd. (Dansk Tyggegummi Fabrik A/S) Chewing gum composition with accelerated, controlled release of active agents
US5488962A (en) 1990-10-10 1996-02-06 Perfetti, S.P.A. Chewing gum which is a substitute for tobacco smoke
US5525351A (en) 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5543424A (en) 1989-12-21 1996-08-06 Pharmacia Ab Smoking substitute
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
GB2299756A (en) 1995-03-29 1996-10-16 Gilbert Falkingham Clayton Gelatinous pastille containing nicotine
US5599554A (en) 1994-06-23 1997-02-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms
WO1997010162A1 (en) 1995-09-13 1997-03-20 Pharmacia & Upjohn Ab Method for marking objects and objects being marked with such method
WO1997041858A1 (en) 1996-05-06 1997-11-13 Pharmacia & Upjohn Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
WO1997042941A2 (en) 1996-05-13 1997-11-20 Novartis Consumer Health S.A. Buccal delivery system
US5711961A (en) 1994-07-26 1998-01-27 Apr Applied Pharma Research S.A. Pharmaceutical compositions based on chewing gum and a method for the preparation thereof
US5783207A (en) 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US5855908A (en) 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US5908614A (en) 1995-08-15 1999-06-01 Montgomery; Robert Eric Peroxidase-activating oral compositions
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
US5935604A (en) 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
US5955099A (en) 1998-04-16 1999-09-21 White; Wendy A. Cough drop sucker with cover
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346100A1 (en) * 1983-12-21 1985-07-04 Beiersdorf Ag Residue-free re-detachable adhesive surfaces
US4587125A (en) 1984-08-27 1986-05-06 Warner-Lambert Company Non-staling chewing gum compositions and improved method of preparation
US4581234A (en) 1984-08-27 1986-04-08 Warner-Lambert Company Non-staling, substantially moistureless chewing gum compositions and improved method of preparation
US4555407A (en) 1984-12-24 1985-11-26 General Foods Corporation Continuous chewing gum method
GB8500862D0 (en) 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
US5824334A (en) 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US4740376A (en) 1986-01-07 1988-04-26 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products
US5110607A (en) 1986-05-20 1992-05-05 Warner-Lambert Company Chewing gum composition and method of making same
US4724151A (en) 1986-10-24 1988-02-09 Warner-Lambert Company Chewing gum compositions having prolonged breath-freshening
US4872884A (en) 1986-12-10 1989-10-10 Warner-Lambert Company Reduced calorie chewing gum base and compositions containing the same
US4915958A (en) 1986-12-10 1990-04-10 Warner-Lambert Company High-base gum composition with extended flavor release
US4981698A (en) 1986-12-23 1991-01-01 Warner-Lambert Co. Multiple encapsulated sweetener delivery system and method of preparation
US5004595A (en) 1986-12-23 1991-04-02 Warner-Lambert Company Multiple encapsulated flavor delivery system and method of preparation
US4975270A (en) 1987-04-21 1990-12-04 Nabisco Brands, Inc. Elastomer encased active ingredients
US4775537A (en) 1987-04-30 1988-10-04 Warner-Lambert Company Sequentially flavored chewing gum composition
IL86170A (en) 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4986991A (en) 1987-05-15 1991-01-22 Wm Wrigley, Jr., Company Chewing gum having an extended sweetness
US4808418A (en) 1987-06-30 1989-02-28 Warner-Lambert Company Heterogenous chewing gum composition and method of preparation
US4822597A (en) 1987-07-13 1989-04-18 Warner-Lambert Company Anesthetic-containing chewing gum compositions
US4842870A (en) 1987-12-22 1989-06-27 Warner-Lambert Company Anhydrous, non-staling chewing gum composition
IT1215726B (en) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Galenic formulations with programmed release.
US4882175A (en) 1988-05-05 1989-11-21 Wm. Wrigley Jr. Company Method for forming a confectionary product into a rolled tape
US5178850A (en) 1988-06-30 1993-01-12 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed liquid pharmaceutical compound
US5013716A (en) 1988-10-28 1991-05-07 Warner-Lambert Company Unpleasant taste masking compositions and methods for preparing same
US4954353A (en) 1988-12-29 1990-09-04 Warner-Lambert Company Anhydrous chewing gum with improved stability
US5169658A (en) 1989-04-19 1992-12-08 Wm. Wrigley Jr. Company Polyvinyl acetate encapsulation of crystalline sucralose for use in chewing gum
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
US4948595A (en) 1989-06-30 1990-08-14 Wm. Wrigley Jr. Company Spearmint enhanced peppermint flavored chewing gum with improved stability
US5139798A (en) 1990-11-21 1992-08-18 Wm. Wrigley Jr. Company Polyvinyl acetate encapsulation of codried sucralose for use in chewing gum
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
US4992280A (en) 1989-12-18 1991-02-12 Columbia Laboratories, Inc. Sustained flavorant release composition, method for making same and chewable structure incorporating same
US5048544A (en) 1990-08-10 1991-09-17 Robert Mascarelli Cigarette substitute
US5149521A (en) 1990-08-31 1992-09-22 Kao Corporation Composition for use in oral cavity
EP0485170B1 (en) 1990-11-06 1995-09-13 Wm. Wrigley Jr. Company Enhanced flavors using menthone ketals
US5100678A (en) 1990-11-15 1992-03-31 Wm. Wrigley Jr. Company Chewing gum with prolonged flavor release incorporating unsaturated, purified monoglycerides
US5227182A (en) 1991-07-17 1993-07-13 Wm. Wrigley Jr. Company Method of controlling release of sucralose in chewing gum using cellulose derivatives and gum produced thereby
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5679389A (en) 1991-07-12 1997-10-21 Warner-Lambert Company Chewing gum compositions having increased flavor and sweetness and methods for preparing same
US5169657A (en) 1991-07-17 1992-12-08 Wm. Wrigley Jr. Company Polyvinyl acetate encapsulation of sucralose from solutions for use in chewing gum
US5266336A (en) 1991-11-12 1993-11-30 Wm. Wrigley Jr. Company High flavor impact non-tack chewing gum with reduced plasticization
GB9127304D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5236721A (en) 1992-02-12 1993-08-17 Columbia Laboratories, Inc. Sustained flavorant release composition, chewable structure incorporating same and method for making same
US5596007A (en) 1992-05-18 1997-01-21 Pharmaco Behavioral Associates, Inc. Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine
US5573774A (en) 1993-02-02 1996-11-12 Keenan; Robert M. Nicotine metabolites, nicotine dependence and human body weight
US5869505A (en) 1993-02-02 1999-02-09 Keenan; Robert M. Nicotine metabolites and nicotine dependence
US5368304A (en) 1993-04-28 1994-11-29 Lisco, Inc. Low spin golf ball
US5405623A (en) 1993-09-22 1995-04-11 Wm. Wrigley Jr. Company Chewing gum compositions and methods for manufacturing same
US6010723A (en) 1993-09-24 2000-01-04 The Wm. Wrigley Jr. Company Method for manufacturing gum base
US6086925A (en) 1993-09-24 2000-07-11 Wm. Wrigley Jr. Company Chewing gum base manufacturing process using plurality of lubricating agents feed inlets
US6004589A (en) 1993-09-24 1999-12-21 Wm. Wrigley Jr. Company Chewing gum base manufacturing process using plurality of filler feed inlet locations
US6238710B1 (en) 1993-09-24 2001-05-29 Wm. Wrigley, Jr. Company Method for continuous gum base manufacture
US5562936A (en) 1993-09-24 1996-10-08 Wm. Wrigley Jr. Company Continuous chewing gum base manufacturing process using highly distribute mixing
US5773053A (en) 1993-09-24 1998-06-30 Wm. Wrigley Jr. Company Chewing gum base manufacturing process using plurality of softening agents inlets
US5486366A (en) 1993-09-24 1996-01-23 Wm. Wrigley Jr. Company Continuous chewing gum base manufacturing process using a mixing-restriction element
US5397580A (en) 1993-10-22 1995-03-14 Wm. Wrigley Jr. Company Continuous gum base manufacture using sequential mixers
US5554380A (en) 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
US6030647A (en) 1994-09-13 2000-02-29 Wm. Wrigley Jr. Company Continuous chewing gum manufacturing process for gum with controlled flavor release
US5545416A (en) 1994-09-13 1996-08-13 Wm. Wrigley Jr. Company Gum base made with reduced antioxidant and method of preparation
CN1067855C (en) 1994-09-13 2001-07-04 Wm·雷格利Jr·公司 Method for continuous gum base manufacturing
US5567450A (en) 1995-06-07 1996-10-22 Wm. Wrigley Jr. Company Gum base manufacturing method
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5843466A (en) 1995-08-29 1998-12-01 V. Mane Fils S.A. Coolant compositions
US5725865A (en) 1995-08-29 1998-03-10 V. Mane Fils S.A. Coolant compositions
US5976581A (en) 1995-09-12 1999-11-02 Wm. Wrigley Jr. Company Continuous chewing gum manufacturing process using rework gum
KR0183524B1 (en) 1995-09-27 1999-04-15 모리 하루오 Navigation system for displaying a structure-shape map 51 g08g 1/0969
US6017565A (en) 1996-02-21 2000-01-25 Wm. Wrigley Jr. Company Method for automated continuous production of chewing gum
US5846557A (en) 1996-03-20 1998-12-08 Cumberland Packing Corporation Chewing gum containing cough suppressing agent
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
EP1005370A2 (en) 1997-02-12 2000-06-07 Nutri Pharma ASA Use of a combination of an anti-smoking composition and a dietary composition in smoking cessation
US5859503A (en) * 1997-04-02 1999-01-12 Nellcor Puritan-Bennett Lamp modulation circuit having a feedback for measuring lamp temperature
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6211194B1 (en) 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6312713B1 (en) 1998-06-12 2001-11-06 Bernard Korol Polymer matrices for storage and sustained release of drugs and chemicals
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
FR2787110B1 (en) 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent and process for the preparation thereof
US6248760B1 (en) 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
BR0109202A (en) 2000-03-14 2002-12-17 Unilever Nv Oral composition, and use of 2'-hydroxypropiophenone
JP2002014872A (en) * 2000-06-29 2002-01-18 Fujitsu Ltd Cipher controller

Patent Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1038227A (en) 1911-07-25 1912-09-10 Nathan Sulzberger Chewing-gum containing pharmaceutical preparations.
US2262087A (en) 1940-05-21 1941-11-11 White Lab Inc Chewing gum tablet
US2536168A (en) 1947-09-29 1951-01-02 Clark & Clark Co Amphetamine chewing gum
US3877468A (en) 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3845217A (en) 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4139589A (en) 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US3984574A (en) 1975-04-11 1976-10-05 Wm. Wrigley Jr. Company Non-tack chewing gum composition
US4163777A (en) 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4276890A (en) 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US4238475A (en) 1979-08-01 1980-12-09 Life Savers Inc. Chewing cum capable of releasing finely divided water-insoluble materials therefrom
US4311691A (en) 1979-10-09 1982-01-19 Fichera Anthony T Tobacco smoking inhibitor
US4515769A (en) 1981-12-01 1985-05-07 Borden, Inc. Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same
US4971079A (en) 1982-02-22 1990-11-20 Talapin Vitaly I Pharmaceutical preparation possessing antinicotine effect and method of producing same in a gum carrier
US4620982A (en) 1982-12-17 1986-11-04 Roquette Freres Pastilles of the lozenge type based on crystalline sorbitol or fructose and process for their manufacture
US4806356A (en) 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US4971806A (en) 1984-01-31 1990-11-20 Warner-Lambert Company Multi-layered chewing gum composition having different rates of flavor release
US5855908A (en) 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US4639368A (en) 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5783207A (en) 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US5132114A (en) 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4907605A (en) 1985-05-24 1990-03-13 Advanced Tobacco Products, Inc. Oral tabacco substitute
US4711784A (en) 1986-01-07 1987-12-08 Warner-Lambert Company Encapsulation composition for use with chewing gum and edible products
US5147648A (en) 1986-01-16 1992-09-15 Christian Bannert Method of improving the adhesiveness of gels to mucosae
US4967773A (en) 1986-06-26 1990-11-06 Shaw Alec S W Nicotine containing lozenge
US4985252A (en) 1987-04-07 1991-01-15 R. I. Ph. Recherche Informatique Et Pharmacie (S.A.R.L.) Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4832994A (en) 1987-09-02 1989-05-23 Fey Michael S Anti-smoking oral composition
US5244668A (en) 1988-10-14 1993-09-14 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4983378A (en) 1988-11-22 1991-01-08 Parnell Pharmaceuticals, Inc. Method and composition for treating xerostomia
US5069904A (en) 1989-01-06 1991-12-03 Elan Corporation, Plc Method of using nicotine in the treatment of conditions susceptible to said treatment
US5139787A (en) 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154927A (en) 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US4963369A (en) 1989-01-19 1990-10-16 Wm. Wrigley Jr. Co. Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154939A (en) 1989-04-19 1992-10-13 Wm. Wrigley Jr. Company Use of salt to improve extrusion encapsulation of chewing gum ingredients
US5198251A (en) 1989-04-19 1993-03-30 Wm. Wrigley Jr. Company Gradual release structures for chewing gum
US5487902A (en) 1989-07-24 1996-01-30 Fertin Laboratories Ltd. (Dansk Tyggegummi Fabrik A/S) Chewing gum composition with accelerated, controlled release of active agents
US5437872A (en) 1989-08-25 1995-08-01 Bioglan Laboratories Ltd. Pharmaceutical compositions and a device for administering the same
US5364627A (en) 1989-10-10 1994-11-15 Wm. Wrigley Jr. Company Gradual release structures made from fiber spinning techniques
US5525351A (en) 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5543424A (en) 1989-12-21 1996-08-06 Pharmacia Ab Smoking substitute
US5147654A (en) 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5488962A (en) 1990-10-10 1996-02-06 Perfetti, S.P.A. Chewing gum which is a substitute for tobacco smoke
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
GB2255892A (en) 1991-05-24 1992-11-25 Charwell Consumer Prod Smoking substitute preparation
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US5312626A (en) 1991-07-01 1994-05-17 Gerhard Gergely Lozenge or chewable tablet
US5158772A (en) 1991-09-23 1992-10-27 Davis Walter B Unique bacterial polysaccharide polymer gel in cosmetics, pharmaceuticals and foods
US5462754A (en) 1992-03-03 1995-10-31 Wm. Wrigley Jr. Company Abhesive chewing gum with improved sweetness profile
WO1993020821A1 (en) 1992-04-21 1993-10-28 Kabi Pharmacia Ab Agents for treating substance abuse disorders
US5302394A (en) 1992-07-14 1994-04-12 Mcneil-Ppc, Inc. Dextromethorphan continuous lozenge manufacturing process
US5334390A (en) 1992-11-05 1994-08-02 Neil Solomon Method for tabacco dehabituation
US5935604A (en) 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
US5399354A (en) 1993-05-28 1995-03-21 Mcneil-Ppc, Inc. Process for making a hard-candy based oral pharmaceutical lozenge containing an antacid
US5662920A (en) 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5593684A (en) 1993-08-04 1997-01-14 Pharmacia Ab Method and therapeutic system for smoking cessation
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5721257A (en) 1993-08-04 1998-02-24 Pharmacia & Upjohn Ab Method and therapeutic system for smoking cessation
WO1995012399A1 (en) 1993-11-01 1995-05-11 Pharmacia Ab Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof
CA2109895A1 (en) 1993-11-24 1995-05-25 Richard Neil Irwin Nicotine containing oral preparation
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US5599554A (en) 1994-06-23 1997-02-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms
US5711961A (en) 1994-07-26 1998-01-27 Apr Applied Pharma Research S.A. Pharmaceutical compositions based on chewing gum and a method for the preparation thereof
GB2299756A (en) 1995-03-29 1996-10-16 Gilbert Falkingham Clayton Gelatinous pastille containing nicotine
US5908614A (en) 1995-08-15 1999-06-01 Montgomery; Robert Eric Peroxidase-activating oral compositions
WO1997010162A1 (en) 1995-09-13 1997-03-20 Pharmacia & Upjohn Ab Method for marking objects and objects being marked with such method
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
US5955098A (en) 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
WO1997041858A1 (en) 1996-05-06 1997-11-13 Pharmacia & Upjohn Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
WO1997042941A2 (en) 1996-05-13 1997-11-20 Novartis Consumer Health S.A. Buccal delivery system
US5955107A (en) 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5955099A (en) 1998-04-16 1999-09-21 White; Wendy A. Cough drop sucker with cover

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Henningfield et al, Abuse Liability and Pharmacodynamic Characteristics of Intravenous and Inhaled Nicotine, 1985, pp. 1-12, The Journal of Pharmacology and Experimental Therapeutics, vol. 234, No. 1.
Henningfield et al, Drinking Coffee and Carbonated Beverages Blocks Absorption of Nicotine From Nicotine Polacrilex Gum, Sep. 26, 1990, pp. 1560-1564, The Journal of the American Medical Association.
Henningfield et al, Nicotine Dependence Interface vbetween Tobacco and Tobacco-related disease, Feb. 1988, pp. 37-53, CHEST.
Nemeth-Coislett et al, Nicotine Gum: dose-related effects on cigarette smoking and subjective ratings, 1987, pp. 424-430, Psychopharmacology.
Nemeth-Coslett et al, Nicotine Gum: Chew Rate, Subjective Effects and Plasma Nicotine, 1988, pp. 747-751, Pharmacology Biochemistry & Behavior, vol. 29.

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039596A1 (en) * 1997-11-14 2002-04-04 Hartoun Hartounian Production of multivesicular liposomes
US20050214229A1 (en) * 1998-09-03 2005-09-29 Jsr, Llc Two-stage transmucosal medicine delivery system for symptom relief
US20050123489A1 (en) * 1998-09-03 2005-06-09 Jsr, Llc Medicated chewing gum delivery system for nicotine
US6893654B2 (en) * 1998-09-03 2005-05-17 Jsr, Llc Two-stage transmucosal medicine delivery system for symptom relief
US20070269417A1 (en) * 1999-05-13 2007-11-22 Mcneight David L Nicotine delivery systems
US20060120974A1 (en) * 1999-05-13 2006-06-08 Fluid Technologies Limited Of Great Britain Nicotine delivery systems
US6834654B2 (en) 2001-05-01 2004-12-28 Regent Court Technologies, Llc Smokeless tobacco product
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US20020162563A1 (en) * 2001-05-01 2002-11-07 Williams Jonnie R. Smokeless tobacco product
WO2003039518A1 (en) * 2001-11-02 2003-05-15 Smithkline Beecham Corporation Oral controlled release forms useful for reducing or preventing nicotine cravings
AU2002340318B2 (en) * 2001-11-02 2007-11-15 Smithkline Beecham Corporation Oral controlled release forms useful for reducing or preventing nicotine cravings
US20040248946A1 (en) * 2001-12-10 2004-12-09 Knight Joseph R Beverage treated with nicotine
US7435749B2 (en) 2001-12-10 2008-10-14 Knight Joseph R Beverage treated with nicotine
US20060105023A1 (en) * 2001-12-10 2006-05-18 Knight Joseph R Treatment of neurological disorders with nicotine
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US20050287226A1 (en) * 2001-12-18 2005-12-29 Sisco Tamea R High potency clinical anti-craving treatment and method of use
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
US20100256210A1 (en) * 2003-01-23 2010-10-07 Singh Nikhilesh N Methods and compositions for delivering 5-ht3 antagonists across the oral mucosa
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
US20100291004A1 (en) * 2004-02-17 2010-11-18 Singh Nikhilesh N Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7658945B2 (en) 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7682628B2 (en) 2004-02-17 2010-03-23 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20080008753A1 (en) * 2004-02-17 2008-01-10 Singh Nikhilesh N Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20070066643A1 (en) * 2005-05-25 2007-03-22 Transoral Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US20080057119A1 (en) * 2005-05-25 2008-03-06 Singh Nikhilesh N Compositions and methods for treating middle-of-the night insomnia
US8252809B2 (en) 2005-05-25 2012-08-28 Transcept Pharmaceuticals, Inc. Compositions for treating insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20100249178A1 (en) * 2005-05-25 2010-09-30 Nikhilesh Singh Compositions and methods for treating middle-of-the-night insomnia
US20100249177A1 (en) * 2005-05-25 2010-09-30 Singh Nikhilesh N Compositions and methods for treating middle-of-the-night insomnia
US20060276501A1 (en) * 2005-05-25 2006-12-07 Transoral Pharmaceuticals, Inc. Solid compositions for treating middle-of-the-night insomnia
US20110039881A1 (en) * 2005-05-25 2011-02-17 Singh Nikhilesh N Compositions and methods for treating middle-of-the-night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US8242131B2 (en) 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US10219999B2 (en) 2006-03-16 2019-03-05 Niconovum Usa, Inc. Snuff composition
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US20070231361A1 (en) * 2006-03-28 2007-10-04 Medtronic Vascular, Inc. Use of Fatty Acids to Inhibit the Growth of Aneurysms
US20080020050A1 (en) * 2006-07-21 2008-01-24 Chau Tommy L Medicinal delivery system, and related methods
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US20100260690A1 (en) * 2007-09-18 2010-10-14 Arne Kristensen Stable chewing gum compositions comprising maltitol and providing rapid release of nicotine
US20090130179A1 (en) * 2007-11-16 2009-05-21 Cadbury Adams Usa Llc Confectionery compositions including markings for delivery of actives
US9511021B2 (en) 2008-05-21 2016-12-06 Novartis, A.G. Tablettable chewing gums
US9763929B2 (en) 2008-05-21 2017-09-19 Novartis, A.G. Tablettable chewing gums
US20110129517A1 (en) * 2008-05-21 2011-06-02 Novartis Ag Tablettable chewing gums
US20110064783A1 (en) * 2008-05-26 2011-03-17 Birgitte Bang-Madsen Flavor Impregnation Of A Chewing Gum Core
US20110214681A1 (en) * 2008-09-17 2011-09-08 Niconovum Ab Process for preparing snuff composition
US8833378B2 (en) 2008-09-17 2014-09-16 Niconovum Ab Process for preparing snuff composition
US20100256215A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Menthol-Melatonin Dissolving Film
US20100256197A1 (en) * 2009-04-02 2010-10-07 Silver Eagle Labs Nv, Llc Nicotine Dissolving Film With Or Without Menthol
US20110038915A1 (en) * 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
WO2011139684A2 (en) 2010-04-28 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
WO2011139811A1 (en) 2010-05-07 2011-11-10 Niconovum Usa, Inc. Nicotine-containing pharmaceutical compositions
EP3284467A1 (en) 2010-05-07 2018-02-21 Niconovum USA, Inc. Nicotine-containing pharmaceutical compositions
WO2013043866A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
WO2013059592A1 (en) 2011-10-21 2013-04-25 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US10463069B2 (en) 2013-12-05 2019-11-05 Juul Labs, Inc. Nicotine liquid formulations for aerosol devices and methods thereof
WO2017093941A1 (en) 2015-12-03 2017-06-08 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
WO2017098443A1 (en) 2015-12-10 2017-06-15 Niconovum Usa, Inc. Protein-enriched therapeutic composition of a nicotinic compound
WO2019239356A1 (en) 2018-06-15 2019-12-19 R. J. Reynolds Tobacco Company Purification of nicotine

Also Published As

Publication number Publication date
US20020102304A1 (en) 2002-08-01
US20020018800A1 (en) 2002-02-14
US6893654B2 (en) 2005-05-17
US20050214229A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
US8871243B2 (en) Disintegrable oral films
US8940772B2 (en) Nicotine lozenge composition
US8689803B2 (en) Systems and methods for effecting cessation of tobacco use
Henningfield Nicotine medications for smoking cessation
ES2592882T3 (en) Multi-portion intra-oral dosage form and use thereof
RU2490010C2 (en) Multicomponent oral dosage form with organoleptic properties
US4946853A (en) Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method
US5703101A (en) Agonist-antagonist combination to reduce the use of nicotine and other drugs
RU2283111C2 (en) Buffered liquid nicotine composition for pulmonary administration
EP0487520B1 (en) Compressed powder medicaments
US6596740B2 (en) Nicotine mucosal spray
EP0619729B1 (en) Composition to help stop smoking
AU2002345454B2 (en) A coated nicotine-containing chewing gum, manufacture and use thereof
JP4898073B2 (en) Fentanyl composition for intranasal administration
AU2007250588B2 (en) Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
US5599554A (en) Treatment of nicotine craving and/or smoking withdrawal symptoms
US5069904A (en) Method of using nicotine in the treatment of conditions susceptible to said treatment
Rose, Ph. D Nicotine addiction and treatment
DK2528617T3 (en) Interleukin-2 or interferon-alpha for use in the treatment of nicotine or eating hung
US5288497A (en) Compositions of oral dissolvable medicaments
US6004970A (en) Smoking cessation treatments using naltrexone and related compounds
Rose Nicotine and nonnicotine factors in cigarette addiction
US8642627B2 (en) Formulation and use thereof
JP4358787B2 (en) Improved nicotine licking agent
Balfour et al. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report

Legal Events

Date Code Title Description
AS Assignment

Owner name: JSR LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PINNEY, JOHN M.;HENNINGFIELD, JACK E.;SHIFFMAN, SAUL;AND OTHERS;REEL/FRAME:012317/0161

Effective date: 20011102

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: JSR NTI LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JSR LLC;REEL/FRAME:019843/0027

Effective date: 20070507

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

FPAY Fee payment

Year of fee payment: 12